Health
FDA authorizes fingerstick COVID-19 antibody test – Mass Device
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Palo Alto, Calif-based Nirmidas Biotech’s MidaSpot rapid COVID-19 antibody combo detection kit uses fingerstick serology testing to detect IgG/IgM antibodies related to the SARS-CoV-2 virus causing COVID-19, according to a news release.
MidaSpot, touted by Nirmidas as the first point-of-care fingerstick COVID-19 test to receive EUA, can now be administered…
-
Noosa News19 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General22 hours agoKen Hinkley has called time at the Power, but he’s the ‘proudest coach the world has seen’
-
Noosa News21 hours agoGovernment stands by funding rules barring youth justice organisations from speaking to media
-
General22 hours agoNatSec Crisis Plan? You guessed it, it’s a secret